Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relugolix vs leuprorelin in androgen-sensitive advanced prostate cancer
CTR20181413Phase 3Completed
- Sponsor
- Takeda
- Start
- Dec 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of tissue-plasminogen activator in prostate cancer (PCa), sponsored by Takeda. Started Dec 2018; status: completed.
02
Drugs
tissue-plasminogen activator
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on CTR20181413.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20181413.